Close Menu

NEW YORK – Resolution Biosciences said Monday that it has entered an agreement with Laboratory Corporation of America to commercialize its Resolution ctDx Lung test.

LabCorp plans to launch the test in the first half of 2020 and will be its exclusive provider with Resolution performing the assay as a laboratory-developed test out of its CLIA facility.

The test uses next-generation sequencing to look for actionable mutations cell-free DNA from non-small cell lung cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.